Ratings Jaguar Health, Inc.

Equities

JAGX

US47010C7065

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
0.0729 USD +5.65% Intraday chart for Jaguar Health, Inc. -8.76% -51.85%

Strengths

  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.

Weaknesses

  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
-51.85% 16.9M - -
+2.56% 108B
B+
+10.02% 104B
B+
+7.74% 23.66B
B
-11.91% 22.1B
B+
-3.29% 19.71B
A-
-35.98% 18.2B
A-
-14.02% 16.19B
B
+4.61% 13.72B
C+
+35.05% 12.22B
C+
Investor Rating
-
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
-
Earnings Growth
-
EBITDA / Sales
-
Profitability
-
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes